| CAS: | 73963-72-1 | |||||||||
| 分子式: | C20H27N5O2 | |||||||||
| 分子量: | 369.45 | |||||||||
| 中文名称: |
| |||||||||
| 英文名称: |
| |||||||||
| 性质描述: | 白色结晶性粉末。熔点157-160℃。 | |||||||||
| 用途: | 抗凝药。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| C797783 | MACKLIN | 西洛他唑 | 10mM in DMSO | 555元/1ml; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
储存：-20°C 状态：白色至米白色固体 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| C2587 | TCI | Cilostazol | >98.0%(HPLC) | 490元/1G; 975元/5G; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
物性(参考值)
相关法规
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 442315 | J&K | Cilostazol | 99%, 一种有效的, 选择性的心血管系统中磷酸二酯酶3亚型PDE 3A的抑制剂, IC50值为0.2 μM | 447元/100MG; 1929元/500MG; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
产品描述 Cilostazol是一种环核苷酸磷酸二酯酶3型(PDE3)抑制剂，IC50为0.2 μM，也抑制腺苷酸的摄取。 靶点（IC50 & Targe） PDE3,0.2μM 体外研究 Cilostazol (OPC-13013)是一个2-氧喹啉衍生物，具有抗血栓形成、舒张血管、抗致有丝分裂、以及强心功效。Cilostazol的舒张血管和抗血栓作用主要是由于抑制了磷酸二酯酶3（PDE3）以及随后细胞内cAMP水平的提高。Cilostazol抑制血小板聚集。[1] Cilostazol也具有抑制腺苷摄入的作用。[3]Cilostazol在心脏中引起的间质腺苷提高抵消了cilostazol的PDE3抑制作用引起的cAMP的升高，因此减弱了强心作用。据报道，Cilostazol能够抑制平滑肌细胞增殖。[2] Cilostazol使血管平滑肌松弛，并引起血管舒张。Cilostazol抑制细胞因子诱导的单核细胞趋化蛋白-1（MCP-1）的表达。Cilostazol降低了血浆中甘油三酯，并提高了血浆中高密度脂蛋白。[4] 参考文献 [1] Cone J, et al. J Cardiovasc Pharmacol, 1999, 34(4), 497-504. [2] Liu Y, et al. Cardiovasc Drug Rev, 2001, 19(4), 369-386. [3] Sun B, et al. J Cardiovasc Pharmacol, 2002, 40(4), 577-585. [4] Schr?r K. et al. Diabetes Obes Metab, 2002, 4 Suppl 2, S14- 安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PHR1503 | Supelco | Cilostazol | Pharmaceutical Secondary Standard; Certified Reference Material | 2411.6元/1 G; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Cilostazol is a dihydro-quinolinone derivative, that is predominantly used as an anti-platelet and vasodilatory agent. It acts by inhibition of cyclic adenosine monophosphate (cAMP) phosphodiesterase, which results in elevation of cAMP levels in platelets and blood vessels, thus inhibiting platelets aggregation. 应用 These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements. 分析说明 These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAA3090 in the slot below. This is an example certificate only and may not be the lot that you receive. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1134153 | USP | Cilostazol | United States Pharmacopeia (USP) Reference Standard | 8048.21元/200 MG; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent. 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 USP issued SDS can be found here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
m.cnreagent.com
